Market Overview

NuPathe Reports Allowance of Added US Patent for ZECUITY


NuPathe Inc. (NASDAQ: PATH) today announced that the United States Patent and Trademark Office has issued a notice of allowance for U.S. Patent application 13/407,434. This application relates to NuPathe's innovative iontophoretic patch that uses a two-stage delivery sequence to transdermally deliver sumatriptan. This, and other proprietary technology, is incorporated into NuPathe's lead product, ZECUITY(R) (sumatriptan iontophoretic transdermal system), the first and only FDA approved patch for migraine.

"This patent allowance is significant for NuPathe as a key technological breakthrough of ZECUITY is its ability to transdermally deliver the most commonly prescribed migraine medication, which cannot be passively absorbed through the skin," said Armando Anido, chief executive officer of NuPathe.

Given this action, NuPathe expects the patent to issue within the next few months. Once issued, the patent will provide additional protection for ZECUITY and will be the sixth patent listed in the U.S. Food & Drug Administration's (FDA) Orange Book. NuPathe has additional U.S. patents covering ZECUITY that expire between 2027 and 2029 and patent applications pending in the U.S. and other territories.

Posted-In: News


Related Articles (PATH)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

ChemoCentryx Issues Top-Line Interim Results for CCX140, Says Data Showed Statistically Significant Reduction in Protein

Casino Stocks Are Up Big—Here's Why